

# Andrew Hantel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2208916/publications.pdf>

Version: 2024-02-01

38  
papers

1,075  
citations

840585

11  
h-index

434063

31  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2118  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	13.9	663
2	Analysis of very elderly (≥80 years) non-Hodgkin lymphoma: impact of functional status and comorbidities on outcome. <i>British Journal of Haematology</i> , 2012, 156, 196-204.	1.2	81
3	Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 73.		46
4	A new family with a germline <i>ANKRD26</i> mutation and predisposition to myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 2945-2946.	0.6	30
5	Validation of a financial toxicity (FT) grading system. <i>Journal of Clinical Oncology</i> , 2017, 35, 6615-6615.	0.8	27
6	Prevalence and Severity of Rationing During Drug Shortages. <i>JAMA Internal Medicine</i> , 2019, 179, 710.	2.6	21
7	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2127-2133.	0.6	20
8	Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224097.	1.1	17
9	Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. <i>Cancer</i> , 2021, 127, 875-883.	2.0	16
10	Imatinib is still recommended for frontline therapy for CML. <i>Blood Advances</i> , 2018, 2, 3648-3652.	2.5	15
11	Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. <i>Blood Advances</i> , 2021, 5, 4352-4360.	2.5	14
12	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. <i>Journal of Oncology Practice</i> , 2016, 12, e901-e911.	2.5	13
13	A rules-based algorithm to identify patients who would benefit from re-addressing advance care planning. <i>Journal of Clinical Oncology</i> , 2017, 35, 4-4.	0.8	13
14	Drug and Vaccine Access in the Ebola Epidemic: Advising Caution in Compassionate Use. <i>Annals of Internal Medicine</i> , 2015, 162, 141-142.	2.0	11
15	Peritransfusion quality-of-life assessment for patients with myelodysplastic syndromes. <i>Transfusion</i> , 2021, 61, 2830-2836.	0.8	10
16	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.	0.8	9
17	Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S184-S185.	0.2	8
18	A protocol and ethical framework for the distribution of rationed chemotherapy. <i>Journal of Clinical Ethics</i> , 2014, 25, 102-15.	0.1	8

#	ARTICLE	IF	CITATIONS
19	US State Government Crisis Standards of Care Guidelines. JAMA Oncology, 2021, 7, 199.	3.4	7
20	Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 636-647.	0.2	6
21	A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. Journal of Clinical Oncology, 2022, 40, 3907-3911.	0.8	6
22	A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. Journal of Palliative Medicine, 2018, 21, 846-849.	0.6	5
23	An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncology, 2020, 6, 469.	3.4	5
24	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia, 2021, 35, 1166-1175.	3.3	5
25	Characterizing terminal oncology ICU hospitalizations.. Journal of Clinical Oncology, 2015, 33, 167-167.	0.8	4
26	Creating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse. Journal of Clinical Oncology, 2018, 36, 2575-2577.	0.8	3
27	Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. Journal of Medical Ethics, 2019, 45, 532-537.	1.0	3
28	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2518-2518.	0.6	3
29	A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncology Practice, 2020, 16, e1098-e1111.	1.4	2
30	A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. Journal of Graduate Medical Education, 2020, 12, 38-43.	0.6	1
31	Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematology, the, 2021, 8, e246-e248.	2.2	1
32	The Impact of Different Ethical Allocation Strategies on Survival during Vincristine Shortages. Blood, 2020, 136, 59-60.	0.6	1
33	Identifying avoidable terminal oncology ICU hospitalizations.. Journal of Clinical Oncology, 2016, 34, 56-56.	0.8	0
34	Qualitative themes underlying potentially avoidable terminal oncology ICU hospitalizations.. Journal of Clinical Oncology, 2017, 35, 101-101.	0.8	0
35	A rules-based algorithm to identify patients who would benefit from re-addressing advanced care planning.. Journal of Clinical Oncology, 2017, 35, e21510-e21510.	0.8	0
36	Themes and costs underlying avoidable terminal oncology ICU hospitalizations.. Journal of Clinical Oncology, 2017, 35, 6548-6548.	0.8	0

#	ARTICLE	IF	CITATIONS
37	The practical ethics of medication shortages: Understanding patient preferences for allocation, decision making, and disclosure through narrative inquiry.. Journal of Clinical Oncology, 2019, 37, e18323-e18323.	0.8	0
38	Stakeholder Perceptions of Barriers to Diverse Acute Myeloid Leukemia Clinical Trial Enrollment at Comprehensive Cancer Centers. Blood, 2021, 138, 3014-3014.	0.6	0